This is a randomized phase 2/3 trial with an expected recruitment of 142 patients recruiting in Norway and soon to be recruiting at multiple centers in Sweden.
One arm gets standard alkylating chemotherapy at recurrence, and the other arm gets standard chemotherapy plus disulfiram and copper.
A proprietary form of disulfiram + copper has been granted orphan drug status by the FDA for GBM.
ReplyDeletehttp://www.cantex.com/content/therapeutic-targets/cx02-for-glioblastoma.htm
https://clinicaltrials.gov/ct2/show/NCT03034135